<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?subarticle report21728?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">F1000Res</journal-id><journal-id journal-id-type="iso-abbrev">F1000Res</journal-id><journal-id journal-id-type="pmc">F1000Research</journal-id><journal-title-group><journal-title>F1000Research</journal-title></journal-title-group><issn pub-type="epub">2046-1402</issn><publisher><publisher-name>F1000Research</publisher-name><publisher-loc>London, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5428514</article-id><article-id pub-id-type="pmid">28529692</article-id><article-id pub-id-type="doi">10.12688/f1000research.10481.1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Note</subject></subj-group><subj-group><subject>Articles</subject><subj-group><subject>Breast Diseases: Benign &amp; Malignant</subject></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Abnormal expression of ATP1A1 and ATP1A2 in breast cancer </plain></SENT>
</text></SecTag></article-title><fn-group content-type="pub-status"><fn><p><text><SENT sid="1" pm="."><plain>[version 1; referees: 2 approved] </plain></SENT>
</text></p></fn></fn-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bogdanov</surname><given-names>Alexey</given-names></name><xref ref-type="corresp" rid="c1">a</xref><xref ref-type="aff" rid="a1">1</xref><xref ref-type="aff" rid="a2">2</xref><xref ref-type="aff" rid="a3">3</xref><xref ref-type="aff" rid="a4">4</xref><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7887-4635</contrib-id></contrib><contrib contrib-type="author"><name><surname>Moiseenko</surname><given-names>Fedor</given-names></name><xref ref-type="corresp" rid="c2">b</xref><xref ref-type="aff" rid="a1">1</xref><xref ref-type="aff" rid="a2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dubina</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="a1">1</xref><xref ref-type="aff" rid="a2">2</xref><xref ref-type="aff" rid="a3">3</xref></contrib><aff id="a1">
<label>1</label>St Petersburg Academic University, St. Petersburg, Russian Federation</aff><aff id="a2">
<label>2</label>Practical Center for Specialized Types of Medical Care (Oncologic), St-Petersburg, Russian Federation</aff><aff id="a3">
<label>3</label>Peter the Great St. Petersburg Polytechnic University, St. Petersburg, Russian Federation</aff><aff id="a4">
<label>4</label>The Petersburg Nuclear Physics Institute, Gatchina, Russian Federation</aff></contrib-group><author-notes><corresp id="c1"><label>a</label><email xlink:href="mailto:aleks_aa@mail.ru">aleks_aa@mail.ru</email></corresp><corresp id="c2"><label>b</label><email xlink:href="mailto:moiseenkofv@gmail.com">moiseenkofv@gmail.com</email></corresp><fn fn-type="con"><p><text><SENT sid="2" pm="."><plain>AB, FM and MD conceptualized the study, collected data and performed data analysis. </plain></SENT>
<SENT sid="3" pm="."><plain>All authors were involved in the writing and revision of the draft manuscript and have agreed to the final content. </plain></SENT>
</text></p></fn><fn fn-type="COI-statement"><p><text><SENT sid="4" pm="."><plain>Competing interests: No competing interests were disclosed. </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="epub"><day>5</day><month>1</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>6</volume><elocation-id>10</elocation-id><history><date date-type="accepted"><day>4</day><month>1</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: © 2017 Bogdanov A et al.</copyright-statement><copyright-year>2017</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="f1000research-6-11294.pdf"/><abstract><p><SecTag type="ABS"><text><SENT sid="5" pm="."><plain>Breast cancer is the first in incidence and the second in death among all solid tumors occurring in women. </plain></SENT>
<SENT sid="6" pm="."><plain>The identification of molecular genetic abnormalities in breast cancer is important to improve the results of treatment. </plain></SENT>
<SENT sid="7" pm="."><plain>In the present study, we analyzed microarray data of breast cancer expression profiling (NCBI GEO database, accession <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65194">GSE65194</ext-link>), focusing on Na +/K +-ATPase coding genes. </plain></SENT>
<SENT sid="8" pm="."><plain>We found overexpression of the ATP1A1 and down-regulation of the ATP1A2. </plain></SENT>
<SENT sid="9" pm="."><plain>We expect that our research could help to improve the understanding of predictive and prognostic features of breast cancer. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group kwd-group-type="author"><kwd>breast cancer</kwd><kwd>Na+/K+-ATPase</kwd><kwd>gene expression</kwd><kwd>abnormality</kwd><kwd>ATP1A1</kwd><kwd>ATP1A2</kwd></kwd-group></SecTag><funding-group><award-group id="fund-1"><funding-source>Ministry of Education and Science of Russian Federation</funding-source><award-id>RFMEFI60414X0070</award-id></award-group><funding-statement>This work was supported by The Ministry of Education and Science of Russian Federation (unique identifier of applied research: RFMEFI60414X0070).</funding-statement></funding-group></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro"><title><text><SENT sid="10" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="11" pm="."><plain>Breast cancer is one of the most common and deadly female solid tumors 1. </plain></SENT>
<SENT sid="12" pm="."><plain>According to reports from Perou et al. 2, further confirmed by other investigators 3, 4, breast cancer is a highly molecularly heterogeneous disease. </plain></SENT>
<SENT sid="13" pm="."><plain>The identification of molecular genetic abnormalities in breast cancer is important to improve the results of treatment and, for instance, to reveal new targets for specific therapies. </plain></SENT>
<SENT sid="14" pm="."><plain>Recent studies based on original retrospective analysis of digitalis use in breast cancer patients have demonstrated the anticancer effect of cardiac glycosides 5 that directly inhibit Na +/K +-ATPase (NKA) activity. </plain></SENT>
<SENT sid="15" pm="."><plain>NKA signaling functions after interaction with cardiac glycosides were also shown 6. </plain></SENT>
<SENT sid="16" pm="."><plain>It seems rational that expression of NKA might influence breast cancer prognosis. </plain></SENT>
</text></p><p><text><SENT sid="17" pm="."><plain>NKA is a significant integral membrane protein. </plain></SENT>
<SENT sid="18" pm="."><plain>NKA’s main function is the creation and maintenance of electrochemical gradients for sodium and potassium ions in the living cell. </plain></SENT>
<SENT sid="19" pm="."><plain>These gradients have critical importance for control of cell volume, osmolarity and resting potential 7, 8. </plain></SENT>
<SENT sid="20" pm="."><plain>The minimal functional NKA consists of two associated alpha- and beta- subunits. </plain></SENT>
<SENT sid="21" pm="."><plain>The catalytic alpha-subunit is responsible for conversion of ATP energy to transport of Na + and K + across cell membranes and has ATP and cardiac glycosides binding sites. </plain></SENT>
<SENT sid="22" pm="."><plain>It may be present in human tissues in four different isoforms (α1, α2, α3, α4 – found only in testicles). </plain></SENT>
<SENT sid="23" pm="."><plain>The beta-subunit is responsible for delivery and insertion of alpha one in cell membranes and has three distinct isoforms in humans (β1, β2, β3) 8– 10. </plain></SENT>
<SENT sid="24" pm="."><plain>NKA subunits are variably expressed in different human tissues 11. </plain></SENT>
<SENT sid="25" pm="."><plain>Changes in the relative expression between different isoforms are associated with a number of pathological processes including malignant transformation 12, 13. </plain></SENT>
<SENT sid="26" pm="."><plain>Both down- and up-regulation of alpha- and beta- subunits were shown in solid tumors of different origin 14– 19. </plain></SENT>
</text></p><p><text><SENT sid="27" pm="."><plain>In the present study, we analyzed public breast cancer expression profiles made using Affymetrix Human Genome U133 Plus 2.0 Array (NCBI GEO database 20, accession <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65194">GSE65194</ext-link>) for the expression of alpha subunits of NKA. </plain></SENT>
<SENT sid="28" pm="."><plain>We found abnormalities in ATP1A1 (coding α1-subunit) and ATP1A2 (coding α2-subunit) expression ( Table 1) in breast cancer samples relative to their expression in normal breast tissue. ATP1A1 was overexpressed approximately 1.5 times in all groups of breast cancer samples (p&lt;0.05). </plain></SENT>
<SENT sid="29" pm="."><plain>Coincidently, ATP1A2 expression decreased by more than 2 times (p&lt;0.05). </plain></SENT>
<SENT sid="30" pm="."><plain>There were no differences observed in the expression of ATP1A3 (coding α3-subunit). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" orientation="portrait" position="anchor"><label>Table 1. </label><caption><title><text><SENT sid="31" pm="."><plain>NKA genes expression in breast cancer samples relative to normal breast tissue. </plain></SENT>
</text></title></caption><table frame="hsides" rules="groups" content-type="article-table"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="32" pm="."><plain>Breast cancer group </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="33" pm="."><plain>Lum A </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="34" pm="."><plain>Lum B </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="35" pm="."><plain>Her2 </plain></SENT>
</text></th><th align="center" valign="middle" rowspan="1" colspan="1"><text><SENT sid="36" pm="."><plain>TNBC </plain></SENT>
</text></th></tr><tr><th align="center" rowspan="1" colspan="1"><text><SENT sid="37" pm="."><plain>Gene </plain></SENT>
</text></th><th align="center" colspan="4" rowspan="1"><text><SENT sid="38" pm="."><plain>Relative expression/(ANOVA P-value) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="39" pm="."><plain>ATP1A1 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="40" pm="."><plain>1.53 (0.009016) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="41" pm="."><plain>1.38 (0.04454) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="42" pm="."><plain>1.66 (0.005926) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="43" pm="."><plain>1.44 (0.015725) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="44" pm="."><plain>ATP1A2 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="45" pm="."><plain>-2.49 (1.85·10 -07) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="46" pm="."><plain>-2.52 (8.50·10 -09) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="47" pm="."><plain>-2.78 (5.48·10 -08) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="48" pm="."><plain>-2.87 (2.08·10-11) </plain></SENT>
</text></td></tr><tr><td align="center" rowspan="1" colspan="1"><text><SENT sid="49" pm="."><plain>ATP1A3 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="50" pm="."><plain>-1.05 (0.429089) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="51" pm="."><plain>1.03 (0.308298) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="52" pm="."><plain>-1.04 (0.768041) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="53" pm="."><plain>-1.04 (0.527878) </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods"><title><text><SENT sid="54" pm="."><plain>Methods </plain></SENT>
</text></title><p><text><SENT sid="55" pm="."><plain>Preanalytical procedures consisted of a robust multichip analysis (RMA) algorithm 21, including background correction, probe set signal integration, and quantile normalization. </plain></SENT>
<SENT sid="56" pm="."><plain>For this purpose, we used Expression Console 1.4 software (Affymetrix, Inc. </plain></SENT>
<SENT sid="57" pm="."><plain>USA). </plain></SENT>
<SENT sid="58" pm="."><plain>We utilized Transcriptome Analysis Console 3.0 software (Affymetrix, Inc. </plain></SENT>
<SENT sid="59" pm="."><plain>USA) to analyze the obtained CHP files and to detect differentially expressed genes using one-way between subjects ANOVA. </plain></SENT>
<SENT sid="60" pm="."><plain>Array data for 41 triple negative samples (TNBC group), 30 Her2-positive (Her2 group), 30 Luminal B (Lum B group), 29 Luminal A (Lum A group) breast cancer samples and 11 normal breast tissue samples were investigated. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec sec-type="conclusions"><title><text><SENT sid="61" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="62" pm="."><plain>Using a public microarray dataset we found abnormalities in the expression of ATP1A1 and ATP1A2 in breast cancer samples. </plain></SENT>
<SENT sid="63" pm="."><plain>This may correlate with digitalis anticancer activity, but requires additional research. </plain></SENT>
<SENT sid="64" pm="."><plain>We expect that our research could help to improve the understanding of predictive and prognostic features of breast cancer. </plain></SENT>
</text></p></sec></SecTag><sec><title><text><SENT sid="65" pm="."><plain>Data and software availability </plain></SENT>
</text></title><p><text><SENT sid="66" pm="."><plain>Raw data for Table 1 are available at: </plain></SENT>
</text></p><p><text><SENT sid="67" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/download/?acc=GSE65194&amp;format=file">https://www.ncbi.nlm.nih.gov/geo/download/?acc=GSE65194&amp;format=file</ext-link> 22. </plain></SENT>
</text></p><p><text><SENT sid="68" pm="."><plain>Expression Console 1.4 software and Transcriptome Analysis Console 3.0 software (Affymetrix, Inc. </plain></SENT>
<SENT sid="69" pm="."><plain>USA) are available after free customer registration at: </plain></SENT>
</text></p><p><text><SENT sid="70" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.affymetrix.com/support/technical/software_downloads.affx">http://www.affymetrix.com/support/technical/software_downloads.affx</ext-link>. </plain></SENT>
</text></p></sec></body><back><SecTag type="REF"><ref-list><ref id="ref-1"><text><SENT sid="71" pm="."><plain>1 SiegelRLMillerKDJemalA: Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. 10.3322/caac.21332 <?supplied-pmid 26742998?>26742998 </plain></SENT>
</text></ref><ref id="ref-2"><text><SENT sid="72" pm="."><plain>2 PerouCMSørlieTEisenMB: Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52. 10.1038/35021093 <?supplied-pmid 10963602?>10963602 </plain></SENT>
</text></ref><ref id="ref-3"><text><SENT sid="73" pm="."><plain>3 SørlieTPerouCMTibshiraniR: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74. 10.1073/pnas.191367098 <?supplied-pmid 11553815?>11553815 </plain></SENT>
</text></ref><ref id="ref-4"><text><SENT sid="74" pm="."><plain>4 SørlieTTibshiraniRParkerJ: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–23. 10.1073/pnas.0932692100 <?supplied-pmid 12829800?>12829800 </plain></SENT>
</text></ref><ref id="ref-5"><text><SENT sid="75" pm="."><plain>5 PrassasIDiamandisEP: Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov. 2008;7(11):926–35. 10.1038/nrd2682 <?supplied-pmid 18948999?>18948999 </plain></SENT>
</text></ref><ref id="ref-6"><text><SENT sid="76" pm="."><plain>6 SchonerWScheiner-BobisG: Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol. 2007;293(2):C509–C36. 10.1152/ajpcell.00098.2007 <?supplied-pmid 17494630?>17494630 </plain></SENT>
</text></ref><ref id="ref-7"><text><SENT sid="77" pm="."><plain>7 SkouJC: The influence of some cations on an adenosine triphosphatase from peripheral nerves. Biochim Biophys Acta. 1957;23(2):394–401. 10.1016/0006-3002(57)90343-8 <?supplied-pmid 13412736?>13412736 </plain></SENT>
</text></ref><ref id="ref-8"><text><SENT sid="78" pm="."><plain>8 SkouJCEsmannM: The Na,K-ATPase. J Bioenerg Biomembr. 1992;24(3):249–61. <?supplied-pmid 1328174?>1328174 </plain></SENT>
</text></ref><ref id="ref-9"><text><SENT sid="79" pm="."><plain>9 McDonoughAAGeeringKFarleyRA: The sodium pump needs its beta subunit. FASEB J. 1990;4(6):1598–605. <?supplied-pmid 2156741?>2156741 </plain></SENT>
</text></ref><ref id="ref-10"><text><SENT sid="80" pm="."><plain>10 MercerRW: Structure of the Na,K-ATPase. Int Rev Cytol. 1993;137C:139–68. <?supplied-pmid 8387469?>8387469 </plain></SENT>
</text></ref><ref id="ref-11"><text><SENT sid="81" pm="."><plain>11 BlancoGMercerRW: Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. Am J Physiol. 1998;275(5 Pt 2):F633–50. <?supplied-pmid 9815123?>9815123 </plain></SENT>
</text></ref><ref id="ref-12"><text><SENT sid="82" pm="."><plain>12 BabulaPMasarikMAdamV: From Na+/K+-ATPase and cardiac glycosides to cytotoxicity and cancer treatment. Anticancer Agents Med Chem. 2013;13(7):1069–87. 10.2174/18715206113139990304 <?supplied-pmid 23537048?>23537048 </plain></SENT>
</text></ref><ref id="ref-13"><text><SENT sid="83" pm="."><plain>13 SuhailM: Na(+), K(+)-ATPase: Ubiquitous Multifunctional Transmembrane Protein and its Relevance to Various Pathophysiological Conditions. J Clin Med Res. 2010;2(1):1–17. 10.4021/jocmr2010.02.263w <?supplied-pmid 22457695?>22457695 </plain></SENT>
</text></ref><ref id="ref-14"><text><SENT sid="84" pm="."><plain>14 SuñolMCusiVCruzO: Immunohistochemical analyses of alpha1 and alpha3 Na+/K+-ATPase subunit expression in medulloblastomas. Anticancer Res. 2011;31(3):953–8. <?supplied-pmid 21498719?>21498719 </plain></SENT>
</text></ref><ref id="ref-15"><text><SENT sid="85" pm="."><plain>15 RajasekaranSAHuynhTPWolleDG: Na,K-ATPase subunits as markers for epithelial-mesenchymal transition in cancer and fibrosis. Mol Cancer Ther. 2010;9(6):1515–24. 10.1158/1535-7163.mct-09-0832 <?supplied-pmid 20501797?>20501797 </plain></SENT>
</text></ref><ref id="ref-16"><text><SENT sid="86" pm="."><plain>16 IngeLJRajasekaranSAYoshimotoK: Evidence for a potential tumor suppressor role for the Na,K-ATPase beta1-subunit. Histol Histopathol. 2008;23(4):459–67. 10.14670/HH-23.459 <?supplied-pmid 18228203?>18228203 </plain></SENT>
</text></ref><ref id="ref-17"><text><SENT sid="87" pm="."><plain>17 EspinedaCSeligsonDBJames BallWJr: Analysis of the Na,K-ATPase alpha- and beta-subunit expression profiles of bladder cancer using tissue microarrays. Cancer. 2003;97(8):1859–68. 10.1002/cncr.11267 <?supplied-pmid 12673711?>12673711 </plain></SENT>
</text></ref><ref id="ref-18"><text><SENT sid="88" pm="."><plain>18 RajasekaranSABallWJJrBanderNH: Reduced expression of beta-subunit of Na,K-ATPase in human clear-cell renal cell carcinoma. J Urol. 1999;162(2):574–80. 10.1016/S0022-5347(05)68629-6 <?supplied-pmid 10411090?>10411090 </plain></SENT>
</text></ref><ref id="ref-19"><text><SENT sid="89" pm="."><plain>19 MijatovicTIngrassiaLFacchiniV: Na+/K+-ATPase alpha subunits as new targets in anticancer therapy. Expert Opin Ther Targets. 2008;12(11):1403–17. 10.1517/14728222.12.11.1403 <?supplied-pmid 18851696?>18851696 </plain></SENT>
</text></ref><ref id="ref-20"><text><SENT sid="90" pm="."><plain>20 EdgarRDomrachevMLashAE: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–10. 10.1093/nar/30.1.207 <?supplied-pmid 11752295?>11752295 </plain></SENT>
</text></ref><ref id="ref-21"><text><SENT sid="91" pm="."><plain>21 IrizarryRABolstadBMCollinF: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31(4):e15. 10.1093/nar/gng015 <?supplied-pmid 12582260?>12582260 </plain></SENT>
</text></ref><ref id="ref-22"><text><SENT sid="92" pm="."><plain>22 GEO accession  <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65194">GSE65194</ext-link>, DuboisT: Expression profiling of breast cancer samples from Institut Curie (Maire cohort) --Affy CDF.2015 <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65194">Reference Source</ext-link>  </plain></SENT>
</text></ref></ref-list></SecTag></back><sub-article id="report21728" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.5256/f1000research.11294.r21728</article-id><title-group><article-title>Referee response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chi</surname><given-names>Jen-Tsan Ashley</given-names></name><xref ref-type="aff" rid="r21728a1">1</xref><role>Referee</role></contrib><aff id="r21728a1">
<label>1</label>Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC, 27708, USA</aff></contrib-group><author-notes><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>10</day><month>5</month><year>2017</year></pub-date><related-article id="d35e1554" related-article-type="peer-reviewed-article" ext-link-type="doi" xlink:href="10.12688/f1000research.10481.1">Version 1</related-article><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve</meta-value></custom-meta></custom-meta-group></front-stub><body><p><text><SENT sid="0" pm="."><plain>I think the analysis is appropriate to examine the relative expression of the ATP1A1 and ATP1A2 among different breast cancer cells. </plain></SENT>
<SENT sid="1" pm="."><plain>The data analysis is standard and appropriate. </plain></SENT>
<SENT sid="2" pm="."><plain>One helpful thing is to validate the findings in other breast cancer expression datasets beyond this discovery dataset. </plain></SENT>
<SENT sid="3" pm="."><plain>Another relevant thing is whether the abnormal expression of these genes are associated with varying clinical outcomes. </plain></SENT>
</text></p><p><text><SENT sid="4" pm="."><plain>I have read this submission. </plain></SENT>
<SENT sid="5" pm="."><plain>I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. </plain></SENT>
</text></p></body></sub-article><sub-article id="report20402" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.5256/f1000research.11294.r20402</article-id><title-group><article-title>Referee response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fedyanin</surname><given-names>Mikhail</given-names></name><xref ref-type="aff" rid="r20402a1">1</xref><role>Referee</role></contrib><aff id="r20402a1">
<label>1</label>Department of Clinical Pharmacology and Chemotherapy, N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation</aff></contrib-group><author-notes><fn fn-type="COI-statement"><p>
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>21</day><month>2</month><year>2017</year></pub-date><related-article id="d35e1609" related-article-type="peer-reviewed-article" ext-link-type="doi" xlink:href="10.12688/f1000research.10481.1">Version 1</related-article><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve</meta-value></custom-meta></custom-meta-group></front-stub><body><p><text><SENT sid="0" pm="."><plain>Over the past years several papers were published concerning prognostic role of ATP1A1 expression in hepatocellular carcinoma, lung cancer, and esophageal cancer. </plain></SENT>
<SENT sid="1" pm="."><plain>The authors of the present study show that increased expression of ATP1A1 observed at all breast cancer phenotypes compared to normal tissue. </plain></SENT>
</text></p><p><text><SENT sid="2" pm="."><plain>I would like to note that the authors studied gene expression only, but did not appreciate the immunohistochemical (IHC) changes in the content of gene products. </plain></SENT>
<SENT sid="3" pm="."><plain>In the absence of data of the IHC expression of ATP1A1, it is desirable to represent the differences in gene expression of ATP1A1 compared to referent genes for membrane transporters ( <ext-link ext-link-type="uri" xlink:href="https://protect-eu.mimecast.com/s/6LQhBxrLYHx">http://bmcmolbiol.biomedcentral.com/articles/10.1186/1471-2199-7-29</ext-link> ). </plain></SENT>
<SENT sid="4" pm="."><plain>Given a sufficiently large number of patients included in the study, it is interesting to evaluate the prognostic and predictive value of these findings. </plain></SENT>
<SENT sid="5" pm="."><plain>But I can conclude that this article is interesting for medical oncologists and molecular biologists. </plain></SENT>
</text></p><p><text><SENT sid="6" pm="."><plain>I have read this submission. </plain></SENT>
<SENT sid="7" pm="."><plain>I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. </plain></SENT>
</text></p></body></sub-article></article>
